fezakinumab(一种IL-22单克隆抗体)治疗常规治疗控制不佳的中重度特应性皮炎成人患者的疗效与安全性:一项随机双盲2a期试验
这项随机双盲安慰剂对照2a期试验评估了静脉注射fezakinumab单药治疗中重度特应性皮炎成人患者的疗效与安全性。第12周时全人群SCORAD下降在两组间无显著差异,但在基线SCORAD≥50的重度患者亚组中,第12周和第20周药物组SCORAD下降显著优于安慰剂组。fezakinumab耐受性良好,末次给药后临床改善持续。
要点
- 全人群中第12周SCORAD下降两组无显著差异(P=0.134)。
- 基线SCORAD≥50的重度亚组中,第12周和第20周药物组SCORAD下降显著优于安慰剂组。
- 常见不良事件为上呼吸道感染,fezakinumab耐受性良好。
核心结论
- fezakinumab耐受性良好,末次给药后临床改善持续。
研究设计与样本
- 随机双盲安慰剂对照2a期试验,成人中重度特应性皮炎患者接受静脉fezakinumab单药治疗每2周一次共10周,随访至20周。
- 主要终点为第12周SCORAD评分较基线的变化。
主要发现
- 第12周全研究人群SCORAD平均下降:fezakinumab组13.8±2.7 vs 安慰剂组8.0±3.1(P=0.134)。
- 重度亚组(基线SCORAD≥50)第12周SCORAD下降:药物组21.6±3.8 vs 安慰剂组9.6±4.2(P=0.029),第20周:药物组27.4±3.9 vs 安慰剂组11.5±5.1(P=0.010)。
- 第12周全人群体表面积受累改善:药物组12.4%±2.4 vs 安慰剂组6.2%±2.7(P=0.009)。
- 重度亚组第12周研究者整体评估下降:药物组0.7±0.2 vs 安慰剂组0.3±0.1(P=0.034)。
- 所有评分在末次给药(10周)后至研究结束(20周)期间持续改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 样本量有限。
- 缺乏湿疹面积和严重度指数及瘙痒数字评定量表的评估。
- 显著性主要在重度特应性皮炎中获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function. OBJECTIVE: Evaluate interleukin 22 blockade in adults with moderate-to-severe atopic dermatitis (AD). METHODS: We performed a randomized, double-blind, placebo-controlled trial with intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, with follow-up assessments until 20 weeks. The change in SCOring AD (SCORAD) score from baseline at 12 weeks served as the primary end point. RESULTS: At 12 weeks, the mean declines in SCORAD for the entire study population were 13.8 ± 2.7 in the fezakinumab arm and 8.0 ± 3.1 in the placebo arm (P = .134). In the severe AD patient subset (with a baseline SCORAD of ≥50), SCORAD decline was significantly stronger in the drug-treated patients than placebo-treated patients at 12 weeks (21.6 ± 3.8 vs 9.6 ± 4.2, P = .029) and 20 weeks (27.4 ± 3.9 vs 11.5 ± 5.1, P = .010). At 12 weeks, improvements in body surface area involvement in the entire population were significantly stronger in the drug-treated than placebo-treated patients (12.4% ± 2.4 vs 6.2% ± 2.7; P = .009), and in the severe AD subset, the decline in Investigator Global Assessment was significantly higher in the drug-treated than placebo-treated patients (0.7 ± 0.2 vs 0.3 ± 0.1; P = .034). All scores showed progressive improvements after last dosing (10 weeks) until end of study (20 weeks). Common adverse events were upper respiratory tract infections. LIMITATIONS: The limited sample size and lack of assessment with Eczema Area and Severity Index and a pruritus numerical rating scale were limiting factors. Significance was primarily obtained in severe AD. CONCLUSION: Fezakinumab was well-tolerated, with sustained clinical improvements after last drug dosing.
引用
- Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018. PMID: 29353025. doi:10.1016/j.jaad.2018.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。